Cognizant (CTSH) Q1 2026 earnings review
Bookings Surge and Financial Services Rebound, But Restructuring Costs Loom
Cognizant delivered a solid Q1 2026, posting 5.8% YoY revenue growth (3.9% in constant currency) that landed in the upper half of guidance. The real standout was a 21% surge in bookings, heavily driven by the Financial Services segment, which appears to have fully rebounded with 10.2% constant currency growth. However, this top-line acceleration comes with significant structural adjustments. Management announced 'Project Leap,' a major restructuring program expected to incur up to $320 million in costs (mostly severance) to streamline operations and fund AI investments. While this move allowed the company to raise its full-year adjusted operating margin guidance, it highlights underlying pressure on organic productivity.
🐂 Bull Case
Q1 bookings grew 21% YoY, netting seven large deals (TCV >$100M) and one mega deal (TCV >$500M). Trailing 12-month bookings hit $29.6B with a healthy 1.4x book-to-bill ratio.
The expected $200-$300 million in-year savings from Project Leap allowed management to raise FY26 Adjusted Operating Margin guidance to 16.0%-16.2%, securing bottom-line expansion despite macro complexities.
🐻 Bear Case
The Health Sciences segment reversed from consistent growth in 2025 to a 0.9% constant currency decline in Q1 2026, likely reflecting ongoing payer regulatory pressures and shifting discretionary spending.
Free cash flow plummeted 50% YoY to $198 million in Q1, driven by weaker operating cash generation ($274M vs $400M in Q1 2025), raising questions about working capital or timing of collections.
⚖️ Verdict: ⚪
Cautiously Bullish. The 21% bookings growth and double-digit recovery in Financial Services provide excellent forward visibility. However, the costly Project Leap restructuring and a surprising contraction in Health Sciences indicate that Cognizant is still heavily optimizing its core business to fund its AI ambitions.
Key Themes
Financial Services Segment Resurgence
Accelerating. The Financial Services vertical—Cognizant's largest segment—grew an impressive 10.2% YoY in constant currency, reaching $1.64 billion. This marks a dramatic acceleration from the ~7% CC growth seen in FY25 and proves that discretionary tech spending and AI modernization cycles are returning to the banking and insurance sectors.
Project Leap Implies Structural Bloat
Management introduced 'Project Leap' to accelerate its operating model and fund AI investments. However, the price tag is steep: $230M to $320M in expected costs, heavily weighted toward employee severance ($200M-$270M). While this will generate $200M-$300M in in-year savings, it suggests that standard operational leverage was insufficient to fund the necessary AI scaling, requiring aggressive headcount actions.
Health Sciences Slips into Contraction
Reversing. After posting strong mid-single to double-digit CC growth throughout 2025, the Health Sciences segment (29.2% of total revenue) unexpectedly shrank 0.9% YoY in constant currency. This reversal contrasts sharply with management's previous narrative that regulatory uncertainty would act as a tailwind for transformation deals.
Scaling the AI Ecosystem
Cognizant's 'AI Builder' strategy is materializing through deep partnerships. The company was selected by OpenAI to scale Codex across enterprise clients and embedded it directly into its own software engineering workflows. Additionally, the launch of 'Agentic Retail CX' on Google Cloud's Gemini Enterprise and a new multi-tenant AI factory powered by Dell and NVIDIA demonstrate a clear pivot from traditional IT services to high-value AI integration.
Complex Macro Environment Persists
Stable but cautious. CEO Ravi Kumar explicitly noted the 'complex macroeconomic environment.' This is reflected in the uneven segment performance: while Financial Services surged, Continental Europe contracted 3.1% YoY, and Health Sciences slipped negative. The company is leaning heavily on large vendor consolidation and AI productivity deals to navigate client caution.
Other KPIs
Reversing. FCF collapsed by nearly 50% YoY from $393 million in 25Q1. Operating cash flow fell to $274 million (from $400 million), driving FCF conversion well below Net Income ($662 million). This points to potential working capital headwinds, timing of collections, or upfront cash outlays for the massive bookings quarter.
Stable. Down significantly from the ~15.8% levels seen in early 2025, indicating a much cooler labor market and better retention. Total headcount grew by 6,000 sequentially to 357,600, positioning the company to execute on the recent 21% bookings surge.
Guidance
Stable. Implies YoY growth of 3.8% to 5.3% (3.2% to 4.7% in constant currency). This is sequentially consistent with Q1's 3.9% CC growth, assuming no significant macroeconomic deterioration.
Stable. Unchanged from prior commentary. Represents 4.0% to 6.5% constant currency growth. With Q1 already delivering near the bottom of this range, the massive bookings momentum must convert smoothly to hit the upper bound.
Accelerating. Raised from prior guidance (which modeled 10-30 bps of expansion). The new range implies 20 to 40 bps of YoY expansion, explicitly driven by the anticipated $200-$300 million net savings from Project Leap.
Stable. Represents 7% to 9% YoY growth, effectively bridging the organic revenue growth with share repurchases ($427M executed in Q1) and margin expansion initiatives.
Key Questions
Health Sciences Contraction Drivers
Health Sciences reversed from mid-single-digit growth last year to a constant currency decline in Q1. Was this driven by specific deal delays, structural budget cuts among payers, or the roll-off of legacy contracts?
Project Leap Severance Details
Project Leap anticipates up to $270M in severance costs to generate up to $300M in in-year savings. Which specific segments, roles, or geographies are being targeted, and how does this align with the 6,000 sequential headcount increase in Q1?
Free Cash Flow Compression
Operating cash flow dropped significantly YoY despite higher net income. Are there specific working capital dynamics or upfront costs associated with the Q1 large deal signings that drove this decline?